We respond to draft NICE decision not to recommend abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to provisionally not recommend breast cancer treatment abemaciclib with fulvestrant for routine use on the NHS in England, following its time on the Cancer Drugs Fund since April 2019. That's because it has not been found to be a cost-effective use of NHS resources.
12 Feb 2021
We respond to breast cancer becoming the most common cancer globally
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
05 Feb 2021
We Respond to Breast Cancer Screening Performance Data for England 2019/20
New figures from NHS Digital, taken from the performance data on the breast screening programme for England between April 2019 and March 2020, show that:
28 Jan 2021
We respond to NHS England breast cancer waiting times for November 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
14 Jan 2021
We respond to NHS England breast cancer waiting times: October 2020
10 Dec 2020
We respond to RxPONDER trial results that suggest postmenopausal women with early-stage breast cancer/low recurrence score could skip adjuvant chemo
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
10 Dec 2020
We respond to the Scotland Cancer Recovery Plan
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
10 Dec 2020
Response to the Spending Review 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
25 Nov 2020
We respond to NHS England breast cancer waiting times: September 2020 and Q2 20/21
NHS England cancer waiting times data from September 2020 show:
12 Nov 2020
We respond to a BMJ Study that provides new estimates of breast cancer risks associated with HRT
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said:
10 Nov 2020
We respond to news that the pandemic ‘threatens research as early career scientists look to leave’
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said,
10 Nov 2020
We support recommendations for faster and wider access to innovative cancer treatments
Mia Rosenblatt, Associate Director of Policy and Influencing at Breast Cancer Now, said:
09 Nov 2020